Trial intelligence / Profile preview

Predictive Risk Score for Capecitabine-Induced Hand-Foot Syndrome

TCTR20250410001Not yet recruiting

Sponsor
N/A
Start
Apr 2025
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Trial of capecitabine, sponsored by N/A. Primary endpoint: Development of predictive risk score. Planned start Apr 2025; status: not yet recruiting.

02

Drugs

capecitabine

Beyond the preview

Go deeper on TCTR20250410001.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on TCTR20250410001.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call